Verrica Pharmaceuticals Inc (VRCA)
$1.34
+0.05
(+3.88%)▲
Performance
- $1.27$1.36$1.34
5.22%
Downside
Day's Volatility :6.62%
Upside
1.47%
- $1.04$11.41$1.34
22.36%
Downside
52 Weeks Volatility :90.88%
Upside
88.26%
Returns
| Period | Verrica Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -84.27% | 3.8% | 0.0% |
6 Months | -80.49% | 10.8% | 0.0% |
1 Year | -63.29% | 18.9% | 0.0% |
3 Years | -89.23% | 22.8% | -20.8% |
Highlights
Market Capitalization | 57.2M |
Book Value | - $0.31 |
Earnings Per Share (EPS) | -1.89 |
Wall Street Target Price | 14.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -293.72% |
Return On Assets TTM | -85.72% |
Return On Equity TTM | -412.98% |
Revenue TTM | 13.9M |
Revenue Per Share TTM | 0.3 |
Quarterly Revenue Growth YOY | 2744.5% |
Gross Profit TTM | 8.3M |
EBITDA | -77.5M |
Diluted Eps TTM | -1.89 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.42 |
EPS Estimate Next Year | -0.87 |
EPS Estimate Current Quarter | -0.42 |
EPS Estimate Next Quarter | -0.34 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 944.78%
Technicals Summary
Sell
Neutral
Buy
Verrica Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Verrica Pharmaceuticals Inc | -30.93% | -80.49% | -63.29% | -89.23% | -90.83% |
 Regeneron Pharmaceuticals, Inc. | -12.78% | 12.27% | 21.13% | 86.55% | 232.53% |
 Novo Nordisk A/s | -12.16% | -3.59% | 19.82% | 145.88% | 361.43% |
 Alnylam Pharmaceuticals, Inc. | 8.63% | 91.46% | 72.01% | 39.76% | 259.26% |
 Vertex Pharmaceuticals Incorporated | -0.52% | 20.07% | 29.39% | 164.22% | 174.3% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Verrica Pharmaceuticals Inc | NA | NA | NA | -1.42 | -4.13 | -0.86 | NA | -0.31 |
Regeneron Pharmaceuticals, Inc. | 26.81 | 26.81 | 1.38 | 45.04 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 39.53 | 39.53 | 1.79 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.38 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.58 | 0.33 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Verrica Pharmaceuticals Inc | Buy | $57.2M | -90.83% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $111.6B | 232.53% | 26.81 | 32.04% |
Novo Nordisk A/s | Buy | $519.8B | 361.43% | 39.53 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.5B | 259.26% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $122.9B | 174.3% | 32.84 | -4.74% |
Insights on Verrica Pharmaceuticals Inc
Increasing Revenue
Revenue is up for the last 3 quarters, 1.98M → 5.17M (in $), with an average increase of 37.1% per quarter
Increasing Net Profit
Netprofit is up for the last 4 quarters, -24.80M → -17.18M (in $), with an average increase of 13.4% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 72.0% return, outperforming this stock by 135.3%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 39.8% return, outperforming this stock by 129.0%
Institutional Holdings
Perceptive Advisors LLC
16.64%venBio Select Advisor LLC
9.37%Vanguard Group Inc
2.98%BlackRock Inc
2.65%FMR Inc
2.60%Geode Capital Management, LLC
1.09%
Company Information
verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.
Organization | Verrica Pharmaceuticals Inc |
Employees | 100 |
CEO | Mr. Ted White |
Industry | Health Technology |
Discover More
Orion Energy Systems Inc
$1.34
+3.88%
Nano Labs Ltd.
$1.34
+3.88%
Innovator Intl Developed Power Buffer Etf - June
$1.34
+3.88%
Bny Mellon Concentrated Intl
$1.34
+3.88%
Fidelity International Multifactor Etf
$1.34
+3.88%
Innovator Us Equity Accelerated Plus Etf - April
$1.34
+3.88%
Amplify Seymour Cannabis Etf
$1.34
+3.88%
Saratoga Investment Corp
$1.34
+3.88%
Ebang International Holdings Inc
$1.34
+3.88%